Valeo Pharma Inc.'s Profile

An innovative Canadian pharmaceutical company with 9 products currently marketed ($40M. estimated peak sales / year) Q2-21 record revenues of $2.65 million , up 27% vs Q2-20 and up 42% over prior quarter. Q3-21 revenues expected to increase by more than 50% over Q2-21.

Featured Posts

Valeo Pharma Reports on Launch of New Corporate Structure
AGORACOM-KE
August 16
Valeo Pharma Inc.
Symbol
VPH
Exchange
CSE
Shares
64,528,834 as of 01/31/2021
Industry
Technology & Medical
Create a Post

Top Members

MAIL ROOM
Last Posted:
0/0/0000
Rating:
Messages:
0

Valeo Pharma Inc.'s Bulletin

Valeo Pharma Reports on Launch of New Corporate Structure Canada NewsWire Sales team expands to 65 bringing total employees to 95 National sales structure now actively deployed in support of Enerzair ®Breezhaler ® and Atectura ® Breezhaler ® Head office and warehouse facility expanded to support sales growth MONTREAL , Aug. 16, 2021 /CNW Telbec/ - Valeo Pharma Inc . (VPH: CSE) (VPHIF: OTCQB) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, announced today that it has completed implementation of its new corporate structure and launched full commercial activities in support of Enerzair Breezhaler triple therapy and Atectura Breezhaler dual therapy, two new asthma medications. The Company is now structured into 2 business units, Respiratory and Specialty Products, led by industry veterans Howard Wiseman and Jean-Charles Leathead respectively. With the completion of a full national sales structure for each business unit, Valeo's sales team has expanded to 65 professionals out of a total of 95 full time employees. The Company has also recently expanded its head office and warehouse capacity to support its recent product launches. "Our Respiratory business unit has deployed full commercial coverage across Canada and we are actively engaging with healthcare professionals in support of Enerzair and Atectura", said Steve Saviuk , CEO. "Our recently completed medical team, headed byNelly Komari , provides us with strong capabilties for our expanding portfolio of innovative drugs. Redesca ® , Enerzair and Atectura are important launches for us and we expect these three products to lead our sales growth. Launched in April, Redesca has quickly become our fastest growing product line and we continue to believe that it will achieve peak revenues of $30M annually". Commenting on the new corporate structure implementation completion, Frederic Fasano , Valeo's President and Chief Operating Officer said, "We are very pleased to have been able to complete the implementation of our new corporate structure and commercially launch three transformative products in such a short period of time. This testifies to the quality of our people in place and of those recently recruited. The successful integration of our dedicated sales teams with the related supportive head office functions will create significant operating leverage over the coming years as we continue to add strategic assets to each business unit and take full advantage of our new corporate structure and commercial platform". About Valeo Pharma Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory Diseases, Neurodegenerative Diseases, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.comand follow us on LinkedIn and Twitter . Forward Looking Statements This press release contains forward-looking statements about Valeo's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.   SOURCE Valeo Pharma Inc.
Redesca™ and Redesca HP™ now covered for public reimbursement in 7 provinces and territories across Canada Private payer health plan coverage in Canada now at 70% MONTREAL , July 13, 2021 /CNW Telbec/ - Valeo Pharma Inc . (VPH: CSE) (VPHIF: OTCQB)("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that Redesca™ and Redesca HP™, its low molecular weight heparin ("LMWH") biosimilar, is now covered for public reimbursement in 7 provinces and territories across the country in addition to several governmental agencies and 70% of privately insured lives in Canada for private payer health plans reimbursement. Amongst Canadian provinces, territories and governmental agencies presently publicly covering Redesca™ and Redesca HP™ for reimbursement are, Alberta , Manitoba , Ontario , New Brunswick , Prince Edward Island , Newfoundland , Northwest Territories , Non Insured Health Benefits for registered First Nations and recognized Inuit and Veterans Affairs Canada. Public reimbursement coverage in the remaining provinces is anticipated by the end of the year. "We are very pleased to have secured public reimbursement coverage for Redesca by a majority of provinces across the country and to be in advanced discussion stages for the remaining provinces. Reimbursement coverage is always a key component of any commercialization strategy in healthcare industry and we are executing according to plan with regards to our Redesca program", said Frederic Fasano , Valeo's President and Chief Operating Officer. "As one of our three transformative products recently launched, Redesca has already started materially impacting our financial performance. Given the positive feedback gathered from the field by our dedicated team, we are confident to see Redesca continue to grow rapidly and help us deliver on its clinical ans medical values, going forward". About Redesca™, Redesca HP™ Redesca is a low molecular weight heparin biosimilar. LMWHs are injectable anticoagulant drugs used primarily to treat and prevent deep vein thrombosis and pulmonary embolism. Redesca has more than 8 years of proven in-market safety internationally. and more than 150 million patient days treated in Europe alone. About Valeo Pharma Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory Diseases, Neurodegenerative Diseases, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter . Forward Looking Statements This press release contains forward-looking statements about Valeo's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. View original content to download multimedia: https://www.prnewswire.com/news-releases/valeo-pharma-announces-additional-provincial-reimbursement-coverage-for-redesca-and-redesca-hp-301332173.html  
Q2-21 record revenues of $2.65 million , up 27% vs Q2-20 and up 42% over prior quarter Q3-21 revenues expected to increase by more than 50% over Q2-21 Redesca launched in late Q2-21 Enerzair® Breezhaler® and Atectura® Breezhaler® commercial shipments commenced following national respiratory sales force deployment Closing of upsized $6.645 million debenture placement Closing of $11.5 million bought deal including full exercise of over-allotment MONTREAL , June 29, 2021 /CNW/ - Valeo Pharma Inc . (VPH:CSE) (VPHIF: OTCQB) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today reported his financial results for the second quarter ended April 30, 2021 . "Our record second quarter revenues saw growth coming from our existing portfolio along with the first indication of the material impact that our three important product launches will bring. Redesca TM was launched at the end of the second quarter and has quickly become our best selling product with sales expected to accelerate for quarters to come. Subsequent to the quarter end, we launched Enerzair ® Breezhaler ® and Atectura ® Breezhaler ® , two innovative asthma therapies.  As a result of these launches, we expect third quarter revenues to expand by more than 50% over our second quarter.", commented Steve Saviuk , CEO. "Public and Private reimbursement coverage for Redesca, Enerzair and Atectura is on track and is a key component to ensure patient's have access to these important medications. We are making significant additions to our corporate and commercial structure in order to accelerate our growth and properly support the potential of our world class products. With senior talent joining our leadership team and the expansion of our medical and field commercial teams,  Valeo is fast positioning itself as a Canadian leader in our defined therapeutic areas". Commenting on the second quarter 2021 results, Luc Mainville , Senior Vice-President and Chief Financial Officer said, "Our revenues continued to progress well along with our margin expansion as a result of launching several new products over the last year. Our net results reflected the addition of head office positions from the creation of our 2 distinct Business Units, Respiratory and  Specialty products as well as the ongoing integration of our growing  national sales force dedicated to the significant market potential of Redesca, Enerzair ® Breezhaler ® and Atectura ® Breezhaler ® products. We expect these three transformative products to fuel our growth over the coming years as we continue adding strategic assets to our portfolio to take full advantage of our new corporate structure and commercial platform." Second Quarter 2021 Financial Results Revenues were $2.65 million for the quarter ended April 30, 2021 compared to $2.1 million for the quarter ended April 30, 2020 representing a 27% increase. The increase over the previous comparable period is mainly due to the strong contribution of new products launched over the past 12 months. The new products launched over the past year, represented 25% of our Q2-21 net revenues and included revenues from Yondelis®, Ametop Gel and Redesca TM which was launched in the final weeks of the quarter but still generated meaningful revenues for the period; Net loss of $1.9 million for the quarter ended April 30, 2021 compared to $0.9 million for the quarter ended April 30, 2020 . The increase in net loss results from the increase in Sales & Marketing, and General & Administrative expenses as Valeo implemented its new commercial structure required to support the expansion of its commercial pipeline including its 3 transformative products, Redesca TM and Enerzair ® Breezhaler ® and Atectura ® Breezhaler ® . Q2-21 results were also impacted by Share-based compensation expenses as Valeo added more senior staff required to position Valeo for revenue growth in 2021 and beyond; and Adjusted EBITDA loss of $1.1 million for the quarter ended April 30, 2021 compared to $0.6 million for the quarter ended April 30, 2020 . The 80% increase can be attributed to respective increase in Sales & Marketing and General & Administrative expenses required to position Valeo for growth in 2021 and beyond. Year to Date 2021 Financial Results Revenues were $4.5 million for the six months ended April 30, 2021 compared to $3.8 million for the six months ended April 30 , 2020. The 20% increase in net revenues is due to the contribution of new products launched over the past 12 months which represented 20% of YTD-21 net revenues; Net loss of $3.6 million for the six months ended April 30, 2021 compared to $2.0 million for the six months ended April 30, 2020 . the increase is mainly due to the respective increase in Sales & Marketing, General & Administrative and Share-Based Compensation expenses; and Adjusted EBITDA loss of $2.2 million for the six months ended April 30, 2021 compared to an Adjusted EBITDA loss of $1.5 million for the six months ended April 30, 2020 . Second Quarter 2021 Business and Product Highlights In April 2021 , after signing a Letter of Intent with pCPA, the Company entered into a Product Listing Agreement with the Executive Officer of the Ontario Public Drug Program for the listing of Redesca® and Redesca HP®, its low molecular weight heparin biosimilar, on the Ontario Drug Benefit Formulary effective April 30, 2021 ; In April 2021 , the Company upsized and closed a $6.645 million non-brokered private placement of unsecured non-convertible debenture units (the "Private Placement"). The Company issued 6,645 unsecured non-convertible debentures units (the "Debenture Units") at a purchase price of $1,000 per Debenture Unit for gross proceeds of $6,645,000 . Each Debenture Unit consist of one (1) unsecured non-convertible debenture of the Company in the principal amount of $1,000 (each, a "Debenture") and 200 Class "A" share purchase warrants (each, a "Warrant"). Each Warrant entitles the holder thereof to purchase one Class "A" Share of the Company (each, a "Share") at an exercise price of $1.60 at any time up to 24 months following the closing date of the Offering (the "Closing Date"). The Debentures will mature at the latest 9 months after the closing and bear interest at a rate of 8% per annum from the date of issue, payable in cash, semi-annually in arrear; In April 2021 , the Company commenced commercial shipments across Canada of Redesca™ and Redesca HP™, its low molecular weight heparin biosimilar; In March 2021 , the Company entered into a Commercial and Supply Agreement with Novartis Pharmaceuticals Canada Inc. for the Canadian commercialization by Valeo of two innovative asthma therapies, Enerzair ® Breezhaler ® and Atectura ® Breezhaler ® ; and In February 2021 , the Company announced that Hesperco™ capsules, approved by Health Canada for immune support, were at the core of the Montreal Heart Institute's ("MHI") clinical trial, "The Hesperidin Coronavirus Study". Subsequent Events In June 2021 , the Company commenced shipping Enerzair® Breezhaler® and Atectura® Breezhaler® across Canada following the start of the deployment of its national respiratory sales force; In June 2021 , the Company entered into an agreement with Research Capital Corporation acting as the lead underwriter and sole bookrunner (the "Lead Underwriter"), on behalf of a syndicate of underwriters (collectively, the "Underwriters"), and issued on a bought-deal basis, 11,500,000 units of the Company (the "Units") at a price of $1.00 per Unit for gross proceeds to the Company of $11,500,000 (the "Offering"), including the full exercise of the over-allotment option. Each Unit were comprised of one common share of the Company (a "Common Share") and one Common Share purchase warrant of the Company (a "Warrant"). Each Warrant shall entitle the holder thereof to purchase one Common Share at an exercise price of $1.25 for a period of 36 months following the closing of the Offering. The net proceeds from the Offering will be used for the purposes described in the final short form prospectus of the Company dated June 22, 2021 ; In May 2021 , the Company announced that private payer health plans currently covering 80% of privately insured lives in Canada have agreed to provide reimbursement for Enerzair Breezhaler and Atectura Breezhaler; and In May 2021 , the Company was accepted for admission into the Innovative Medicines Canada ("IMC") Association as a full member. IMC has represented Canada's innovative pharmaceutical industry since 1914, with 47 members across the spectrum of small, mid-size and large national and multi-national companies. The association plays a central advocacy role in all major issues related to the pharmaceutical industry, including price reform and the pan-canadian rare disease strategy, amongst others. Q2 2021 Webcast and Conference Call Valeo will host a conference call to discuss its second quarter 2021 results and highlights on Wednesday June 30, 2021 at 8.30am (ET) . The telephone numbers to access the conference call are 416-764-8659 and 1-888-664-6392. An audio replay of the call will be available. The numbers to access the audio replay are 416-764-8677 and 1-888-390-0541 using the following access code (069481 #). A live audio webcast of the conference call will be available via: https://produceredition.webcasts.com/starthere.jsp?ei=1475484&tp_key=8148c88363 Financial Statements and MD&A Valeo Pharma's financial statements and Management's Discussion and Analysis for the three and six month periods ended April 30, 2021 are available on SEDAR at www.sedar.com About Valeo Pharma About Valeo Pharma Valeo Pharma is a pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respirology, Neurodegenerative Diseases, Oncology and other specialty products. Headquartered in Kirkland, Quebec , Valeo Pharma has the full capability and complete infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter. Forward Looking Statements This press release contains forward-looking statements about Valeo's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. SOURCE Valeo Pharma Inc.  View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2021/29/c6697.html